Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan

THOUSAND OAKS, Calif. and TOKYO, July 13, 2016 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo; TSE: 4568) today announced the execution of an exclusive agreement to commercialize ni... BiopharmaceuticalsAmgen, Daiichi Sankyo, biosimilars, adalimumab, bevacizumab, trastuzumab
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news